Biosafety level (BSL)-3 facilities exist in a diffuse regulatory environment, where requirements depend on factors such as the kinds of pathogens under study, the type of research being conducted, and ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.

Influenza A (H1N1)pdm09 Virus Therapeutics and Challenges Shailendra K Saxena; Rosaiah Kotikalapudi; Sneham Tiwari; Charuvaka Muvva Disclosures Future Virology. 2012;7 (10):947-950.

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...